RVMD Revolution Medicines Inc
Company Analysis
Latest News
Baker Bros. Nearly Doubles Revolution Medicines Stake, Exits Three
In its second-quarter 13F filing, specialist investment firm Baker Bros. Advisors revealed a portfolio valued at $19.96 billion. As a prominent and highly...
Revolution Medicines' second quarter loss widens as it raises FY26 expense guidance to $2.1B-$2.2B
Revolution Medicines reported a wider-than-expected second quarter net loss of $644.4 million, or ($3.06) per share, missing the consensus estimate of a $1.93...
Revolution Medicines Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Revolution Medicines is expected to report a Q2 2026 consensus revenue of $1.8 million and an adjusted EPS loss of $1.93, while the stock currently trades at...
Revolution Medicines Reports 82% Response Rate for Targeted Pancreatic Cancer Therapy
Revolution Medicines presented Phase 1/2 trial data for its cancer therapy, zoldonrasib, at the ESMO Gastrointestinal Cancers Congress. The studies evaluated...
Revolution Medicines Joins Russell 1000 Growth, Needham Hikes Target to $235
Revolution Medicines joined the Russell 1000 Growth Benchmark on June 29, 2026. This inclusion increases the company's visibility among institutional investors...
🟢 RVMD extends move to 5.3% up
RVMD is trading at $191.79, up 5.3% versus the comparison close of $182.08 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 RVMD is trading 4.4% up today as analysts hike price targets and reaffirm Buy ratings
RVMD is trading 4.4% up at $190.08 after several bullish analyst actions raised price targets and reaffirmed Buy ratings. • The stock is extending its recent...